Voyager Therapeutics (VYGR) Competitors $2.99 -0.16 (-5.08%) Closing price 05/22/2025 04:00 PM EasternExtended Trading$3.04 +0.04 (+1.51%) As of 05/22/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VYGR vs. NAGE, VIR, AVXL, NUVB, QURE, IMNM, AVBP, TRVI, PHAR, and DAWNShould you be buying Voyager Therapeutics stock or one of its competitors? The main competitors of Voyager Therapeutics include Niagen Bioscience (NAGE), Vir Biotechnology (VIR), Anavex Life Sciences (AVXL), Nuvation Bio (NUVB), uniQure (QURE), Immunome (IMNM), ArriVent BioPharma (AVBP), Trevi Therapeutics (TRVI), Pharming Group (PHAR), and Day One Biopharmaceuticals (DAWN). These companies are all part of the "pharmaceutical products" industry. Voyager Therapeutics vs. Niagen Bioscience Vir Biotechnology Anavex Life Sciences Nuvation Bio uniQure Immunome ArriVent BioPharma Trevi Therapeutics Pharming Group Day One Biopharmaceuticals Niagen Bioscience (NASDAQ:NAGE) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap manufacturing companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, community ranking, risk, earnings, profitability, media sentiment and valuation. Does the MarketBeat Community prefer NAGE or VYGR? Voyager Therapeutics received 401 more outperform votes than Niagen Bioscience when rated by MarketBeat users. CompanyUnderperformOutperformNiagen BioscienceN/AN/AVoyager TherapeuticsOutperform Votes40167.97% Underperform Votes18932.03% Do institutionals and insiders believe in NAGE or VYGR? 15.4% of Niagen Bioscience shares are held by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are held by institutional investors. 9.4% of Niagen Bioscience shares are held by insiders. Comparatively, 6.4% of Voyager Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is NAGE or VYGR more profitable? Voyager Therapeutics has a net margin of 15.80% compared to Niagen Bioscience's net margin of 0.00%. Voyager Therapeutics' return on equity of 8.33% beat Niagen Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets Niagen BioscienceN/A N/A N/A Voyager Therapeutics 15.80%8.33%6.15% Which has more volatility & risk, NAGE or VYGR? Niagen Bioscience has a beta of 1.94, indicating that its share price is 94% more volatile than the S&P 500. Comparatively, Voyager Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Do analysts prefer NAGE or VYGR? Voyager Therapeutics has a consensus price target of $13.39, indicating a potential upside of 347.83%. Given Voyager Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Voyager Therapeutics is more favorable than Niagen Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Niagen Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Voyager Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Does the media refer more to NAGE or VYGR? In the previous week, Voyager Therapeutics had 4 more articles in the media than Niagen Bioscience. MarketBeat recorded 6 mentions for Voyager Therapeutics and 2 mentions for Niagen Bioscience. Voyager Therapeutics' average media sentiment score of 0.74 beat Niagen Bioscience's score of 0.58 indicating that Voyager Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Niagen Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Voyager Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation and earnings, NAGE or VYGR? Voyager Therapeutics has lower revenue, but higher earnings than Niagen Bioscience. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNiagen Bioscience$107.93M7.42$13.39M$0.1759.76Voyager Therapeutics$66.96M2.47$132.33M-$1.46-2.05 SummaryVoyager Therapeutics beats Niagen Bioscience on 12 of the 18 factors compared between the two stocks. Get Voyager Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VYGR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VYGR vs. The Competition Export to ExcelMetricVoyager TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$165.46M$2.93B$5.33B$8.39BDividend YieldN/A1.68%5.21%4.11%P/E Ratio4.2131.1826.7119.71Price / Sales2.47398.76386.12120.59Price / Cash1.41168.6838.2534.62Price / Book0.563.236.774.50Net Income$132.33M-$72.35M$3.23B$248.22M7 Day Performance-8.84%5.01%1.80%0.56%1 Month Performance-11.28%5.63%11.10%13.17%1 Year Performance-63.98%-27.04%17.11%7.30% Voyager Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VYGRVoyager Therapeutics4.663 of 5 stars$2.99-5.1%$13.39+347.8%-64.0%$174.31M$66.96M4.21100NAGENiagen BioscienceN/A$9.39+4.9%N/AN/A$738.84M$99.60M55.24120News CoverageVIRVir Biotechnology2.9075 of 5 stars$5.30+4.1%$32.86+519.9%-59.5%$731.74M$14.30M-1.35580News CoveragePositive NewsAnalyst ForecastAnalyst RevisionAVXLAnavex Life Sciences3.8625 of 5 stars$8.55+3.6%$44.00+414.6%+70.4%$729.93MN/A-15.5540NUVBNuvation Bio3.7109 of 5 stars$2.15+2.6%$7.83+265.2%-31.6%$726.47M$7.87M-0.9960Positive NewsGap UpQUREuniQure2.9641 of 5 stars$13.15+2.8%$37.82+187.6%+202.2%$720.30M$27.12M-2.65500Options VolumeAnalyst RevisionIMNMImmunome2.6282 of 5 stars$7.94+6.4%$25.33+219.1%-41.3%$690.88M$9.04M-0.9840Positive NewsAnalyst UpgradeAVBPArriVent BioPharma0.9967 of 5 stars$19.99-0.8%$39.00+95.1%+3.7%$680.56MN/A-7.7840Analyst ForecastTRVITrevi Therapeutics3.4699 of 5 stars$6.70+1.5%$17.56+162.1%+127.5%$669.28MN/A-15.2320News CoveragePositive NewsAnalyst ForecastPHARPharming Group1.7762 of 5 stars$9.81-2.2%$30.00+206.0%+13.3%$667.04M$297.20M-37.71280DAWNDay One Biopharmaceuticals2.7434 of 5 stars$6.58+2.0%$30.57+364.6%-57.1%$666.96M$161.92M-6.3960 Related Companies and Tools Related Companies Niagen Bioscience Alternatives Vir Biotechnology Alternatives Anavex Life Sciences Alternatives Nuvation Bio Alternatives uniQure Alternatives Immunome Alternatives ArriVent BioPharma Alternatives Trevi Therapeutics Alternatives Pharming Group Alternatives Day One Biopharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VYGR) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Voyager Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Voyager Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
